# DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Source: https://onco.cc/trials/nct05882058/  
OnCo record `nct05882058` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of BI 764532, dose 1 in small-cell lung cancer and neuroendocrine tumours, run by Boehringer Ingelheim, now recruiting.

## Summary

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers is a phase 2 interventional study registered as NCT05882058 by Boehringer Ingelheim, with 204 participants planned, started 2023-10-13 and due to reach its primary completion in 2027-12-17. Interventions recorded: BI 764532, dose 1, BI 764532, dose 2 and Ventana DLL3 RxDx assay.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05882058
- Phase: 2
- Setting: DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas
- Sponsor: Boehringer Ingelheim
- Enrolled: 204

## Sources

- ClinicalTrials.gov NCT05882058: https://clinicaltrials.gov/study/NCT05882058

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [Boehringer Ingelheim](https://onco.cc/companies/boehringer-ingelheim/)

---
JSON: https://onco.cc/api/v1/entities/nct05882058.json